Navarro Alonso José Antonio, Limia Sánchez Aurora
Consultor Honorario Permanente de la Dirección General de Salud Pública, Ministerio de Sanidad. Madrid. España.
Área de Programas de Vacunación, Dirección General de Salud Pública, Ministerio de Sanidad. Madrid. España.
Rev Esp Salud Publica. 2022 Sep 7;96:e202209066.
After about a year and a half (at the moment these lines are being written) since the start of the massive vaccination campaign in which, thanks to the high coverage achieved in all groups eligible for vaccination, it has been possible to significantly reduce the morbidity and mortality due to COVID-19, it is important to review the scientific basics that have supported the recommendations implemented to date and those that could be adopted in the near future taking into consideration the epidemiological situation. The objective of this article is, therefore, to address the foundations of some of the technical decisions proposed by the Committee on Programme and Registry of Vaccinations (National Immunization Technical Advisory Group in Spain) and the Technical Working Group on Vaccination against COVID-19. Throughout the eleven updates of the Vaccination Strategy against COVID-19 in Spain, several issues pose intense debate as the vaccination intervals between doses, the convenience of using different types of vaccines, the use of heterologous schemes of vaccination, the benefits of hybrid immunity and the use of a fourth dose (second booster dose) for selected populations. All this without forgetting essential aspects of safety of vaccines. This article is divided into the following sections: Vaccination intervals; Heterologous or mixed scheme; Hybrid immunity (vaccination after infection and infection after vaccination [breakthrough]); Second booster dose.
自大规模疫苗接种运动开始约一年半(在撰写这些内容之时)以来,由于在所有符合接种条件的群体中实现了高覆盖率,已能够显著降低因新冠病毒病(COVID-19)导致的发病率和死亡率。考虑到流行病学情况,回顾迄今支持所实施建议以及近期可能采用的建议的科学依据非常重要。因此,本文的目的是探讨疫苗接种计划与登记委员会(西班牙国家免疫技术咨询小组)和新冠病毒病疫苗接种技术工作组提出的一些技术决策的基础。在西班牙新冠病毒病疫苗接种策略的十一次更新中,几个问题引发了激烈辩论,如剂量之间的接种间隔、使用不同类型疫苗的便利性、使用异源接种方案、混合免疫的益处以及为特定人群使用第四剂(第二剂加强针)。所有这些都不能忘记疫苗安全性的重要方面。本文分为以下几个部分:接种间隔;异源或混合方案;混合免疫(感染后接种疫苗和接种疫苗后感染[突破性感染]);第二剂加强针。